Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly CompanyfiledCriticalEli Lilly Company
Priority to YU12396ApriorityCriticalpatent/YU12396A/en
Publication of YU12396ApublicationCriticalpatent/YU12396A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Ovaj pronalazak obezbedjuje postupak za pripremanje kristalnog anhidratnog oblika jedinjenja formule (I)koji obuhvata izlaganje kristalnog anhidratnog oblika jedinjenja formule (I) relativnoj vlažnosti od oko 90 do oko 100%, a takodje obezbedjuje postupak za pripremanje kristalnog anhidratnog oblika jedinjenja formule (I) koji obuhvata sušenje kristalnog izopropanolatnog oblika jedinjenja formule (I) na temperaturi od oko 50В°C do oko 100В°C, i postupak za pripremanje kristalnog monohidratnog oblika jedinjenja formule (I) koji obuhvata izlaganje kristalnog anhidratnog oblika jedinjenja formule (I) relativnoj vlažnosti od oko 90 do oko 100%.The present invention provides a process for preparing a crystalline anhydrous form of a compound of formula (I) comprising exposing a crystalline anhydrous form of a compound of formula (I) to a relative humidity of about 90 to about 100%, and also provides a process for preparing a crystalline anhydrous form of a compound of formula (I) which comprising drying the crystalline isopropanolate form of the compound of formula (I) at a temperature of from about 50V ° C to about 100V ° C, and a process for preparing the crystalline monohydrate form of the compound of formula (I) comprising exposing the crystalline anhydrous form of the compound of formula (I) to a relative humidity of about 90 to about 100%.
YU12396A1996-02-291996-02-29
PROCEDURE FOR PREPARATION OF LORAKARBEG MONOHYDRATE
YU12396A
(en)
DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE.